HIV prevention has entered a new and exciting era. In lieu of discovering an HIV cure or developing an effective vaccine, 'combination prevention' is likely to underpin HIV prevention globally over coming decades 1 . Within the combination prevention framework, the concept of treatment as prevention (TasP) is attracting the most enthusiasm 2 .
The basic premise of TasP is that commencing HIV infected people on antiretroviral therapy (ART) as soon as possible after their diagnosis will not only benefit them individually (their HIV will not advance) but will also have a broader public health benefit, by reducing their viral load and thus the risk of ongoing HIV transmission. As evidence for pre-exposure prophylaxis as an effective prevention tool continues to mount, so too does ecological 3 , modelling 4 and randomised control trial data 5 supporting reduced HIV transmission through TasP. While recognising the importance of such advances it is also important to recognise that the success of these strategies is predicated on a series of assumptions.
The first assumption is that HIV infection is detected early, particularly among people at high risk of transmitting the virus to others.
While HIV acquisition occurs as a result of individual risk behaviours, In the era of TasP it will be essential that we maintain and build upon previously successful programs to reduce HIV transmission and manage HIV infected patients in Australia. As in the past, it will be critical this work is undertaken as a partnership between the affected community, government, researchers and health service providers. Under the Microscope
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